Metformin Targets Aging and Cancer Through Seven Interconnected Pathways
A comprehensive review reveals metformin's polypharmacological mechanisms—from AMPK activation to gut microbiome remodeling—that may delay aging and enhance cancer immunotherapy.
Summary
This 2025 review in Cancers synthesizes how metformin, a cheap diabetes drug, operates through at least seven interconnected biological systems to potentially slow aging and fight cancer. It activates AMPK, inhibits mitochondrial Complex I, remodels epigenetic marks, expands beneficial gut bacteria like Akkermansia muciniphila, repolarizes tumor-associated macrophages, reduces senescence-associated inflammation, and enhances CAR-T cell performance. Key clinical trials including UKPDS, CAMERA, MA.32, METTEN, and the ongoing TAME trial (3,000 non-diabetic adults, 1500 mg/day metformin) are reviewed. The authors conclude metformin is a uniquely affordable, multi-target candidate for extending healthspan, though biomarker-driven personalization and optimal combination strategies remain to be established.
Detailed Summary
Metformin has been used clinically since the 1950s, but its biology is proving far richer than simple glucose-lowering. This comprehensive 2025 review from RAK Medical and Health Sciences University synthesizes preclinical, epidemiological, and clinical trial evidence to frame metformin as a prototype 'gerotherapeutic' — a drug that targets the fundamental biology of aging rather than just individual diseases. The authors conducted a systematic PubMed/Scopus search covering the past decade, applying Boolean keyword strategies and standardizing data extraction across experimental, translational, and clinical studies in non-diabetic populations.
At the molecular level, metformin binds the ND3 subunit of mitochondrial Complex I, partially inhibiting proton pumping by approximately 67%, which raises the AMP/ATP ratio and activates AMPK. In the liver, this leads to CRTC2 inactivation and suppression of gluconeogenic enzymes PEPCK (−72%) and G6Pase (−68%). In skeletal muscle, AMPK drives GLUT4 translocation (+58%) and PGC-1α-mediated mitochondrial biogenesis. These metabolic actions translate into reduced circulating insulin and IGF-1, which suppress AKT phosphorylation and downstream pro-proliferative signaling in tumor cells — a key indirect anticancer mechanism.
Metformin's epigenetic effects are equally striking. AMPK-driven phosphorylation of histone H2B at serine 36 (H2BS36ph) induces chromatin remodeling that reactivates tumor suppressor genes including p21, promoting cell cycle arrest. Epigenetic markers near longevity genes FOXO3 and SIRT1 are favorably altered, and senescence-associated circRNAs (including circRNA_0001805) are downregulated — effects that translate into measurable reductions in biological age as assessed by validated epigenetic clocks. Metformin also generates a modest 1.8-fold increase in mitochondrial ROS, sufficient to activate NRF2 antioxidant defenses in a manner analogous to exercise or caloric restriction.
In oncology, metformin reshapes the tumor microenvironment by reducing lactate and HIF-1α, repolarizing immunosuppressive M2 macrophages toward the pro-inflammatory M1 phenotype, and increasing cytotoxic T-cell infiltration. An innovative application involves metformin-loaded alginate hydrogel scaffolds implanted at tumor sites: this delivery method enhances CAR-T cell oxidative phosphorylation, promotes a long-lived activated CAR-T phenotype, reduces tumor hypoxia, and improves efficacy against both local and distant tumors while limiting systemic toxicity. Epidemiological data show that in diabetic patients, low-dose metformin (≤500 mg/day) reduced colorectal cancer risk to near non-diabetic levels (adjusted HR 0.36 in women) and dramatically cut liver cancer incidence in men (adjusted HR 0.06).
The landmark TAME trial — 3,000 non-diabetic adults aged 65–79, randomized to 1,500 mg/day metformin or placebo for four years — is designed with 90% power to detect a 22.5% reduction in a composite of cardiovascular disease, cancer, cognitive decline, and mortality. This trial may establish the first regulatory pathway for an aging-targeted indication. The authors acknowledge that tissue-specific dose-response relationships, optimal combination strategies with senolytics or rapalogs, and robust predictive biomarkers remain undefined. The review was unfunded and relied on secondary synthesis rather than new primary data, which limits causal inference.
Key Findings
- Low-dose metformin (≤500 mg/day) reduced colorectal cancer risk in diabetic women to an adjusted HR of 0.36 and liver cancer risk in men to an adjusted HR of 0.06 — near non-diabetic baseline levels
- Metformin inhibits mitochondrial Complex I proton pumping by approximately 67%, raising AMP/ATP ratio and activating AMPK, the master metabolic energy sensor
- Hepatic gluconeogenic enzymes PEPCK and G6Pase are suppressed by 72% and 68% respectively via CRTC2 inactivation downstream of AMPK activation
- GLUT4 translocation in skeletal muscle increases by 58% following AMPK activation, improving insulin sensitivity and glucose uptake
- Metformin generates a modest 1.8-fold increase in mitochondrial ROS — sufficient to activate NRF2 antioxidant defenses without inducing oxidative damage, mimicking effects of exercise
- The TAME trial targets a 22.5% reduction in composite age-related disease incidence (CVD, cancer, cognitive decline, mortality) across 3,000 non-diabetic adults aged 65–79 on 1,500 mg/day over four years
- Metformin-loaded alginate hydrogel CAR-T scaffold delivery enhanced T-cell infiltration and antitumor efficacy against both local and distant tumors while minimizing systemic immune toxicity
Methodology
This is a narrative/systematic review rather than a primary clinical trial. The authors searched PubMed and Scopus across the past decade using Boolean keyword combinations. Inclusion required non-diabetic populations, English language, and full-text access; a standardized extraction template captured design, dosage, outcomes, and safety data. Commentary, abstracts lacking full data, and non-peer-reviewed sources were excluded.
Study Limitations
This is a review article based on secondary synthesis; it cannot establish causality or define optimal dosing without dedicated primary trials. The authors note that tissue-specific dose-response relationships, robust predictive biomarkers, and ideal combination strategies with senolytics or rapalogs remain undefined. No external funding was received, but as a review heavily synthesizing existing literature, publication bias in the underlying primary studies may have inflated apparent effect sizes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: